Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: Type 1 Diabetes


Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis

March 3rd 2021

Nearly a quarter of the type 1 diabetes mellitus patients were affected by metabolic syndrome. Therefore, more attention should be paid to the prevention and control of the epidemic and for the reduction of the morbidity and mortality associated with metabolic syndrome among type 1 diabetes mellitus patients (Diabetes and Metabolic Syndrome)

Categories: News, Obesity
Tags: metabolic syndrome, Type 1 Diabetes

Categories: Obesity
Tags: metabolic syndrome, Type 1 Diabetes

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

March 2nd 2021

The combination of anti-IL-21 and liraglutide could preserve β-cell function in recently diagnosed type 1 diabetes. The efficacy of this combination appears to be similar to that seen in trials of other disease-modifying interventions in type 1 diabetes, but with a seemingly better safety profile (The Lancet Diabetes & Endocrinology)

Categories: News, Treatment
Tags: liraglutide, Type 1 Diabetes, β-cell

Categories: Treatment
Tags: liraglutide, Type 1 Diabetes, β-cell

The DAFNEplus programme for sustained type 1 diabetes self‐management: Intervention development using the Behaviour Change Wheel

March 1st 2021

This method provided a systematic approach to specifying and revising a behaviour change intervention incorporating stakeholder input. The revised DAFNEplus intervention aims to support the maintenance of behavioural changes by targeting barriers and enablers to sustaining self‐management behaviours (Diabetic Medicine)

Categories: Management, News
Tags: DAFNEplus, Type 1 Diabetes

Categories: Management
Tags: DAFNEplus, Type 1 Diabetes

Ready or not? Greater readiness for independent self‐care predicts better self‐management but not HbA1c in teens with type 1 diabetes

February 18th 2021

The current findings may point to a disconnect between how increased readiness for independent self‐care may translate into better perceived diabetes self‐management, but not into better HbA1c. In an effort to optimize HbA1c in teens with type 1 diabetes, future research is needed to design interventions that align perceived readiness for independent self‐care with self‐care behaviours that improve HbA1c (Diabetic Medicine)

Categories: Management, News
Tags: HbA1c, teens, Type 1 Diabetes

Categories: Management
Tags: HbA1c, teens, Type 1 Diabetes

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes

February 7th 2021

SGLT2i improved day‐to‐day glucose variability and time in the target glucose range, without increasing frequency of hypoglycemia, in patients with type 1 diabetes, and reduced glycated hemoglobin, body mass and the required insulin dose (Journal of Diabetes Investigation)

Categories: Medication, News
Tags: SGLT2 inhibitors, Type 1 Diabetes

Categories: Medication
Tags: SGLT2 inhibitors, Type 1 Diabetes

Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia

February 4th 2021

β Cell function can persist in long-duration T1DM. With a peak C-peptide concentration of >0.03 nmol/L, we observed clinically meaningful reductions in the prevalence of severe hypoglycemia (Journal of Clinical Investigation)

Categories: News, Pathology
Tags: hypoglycemia, Type 1 Diabetes, β-cell

Categories: Pathology
Tags: hypoglycemia, Type 1 Diabetes, β-cell

Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study

January 29th 2021

Our data highlight persistent adverse pregnancy outcomes in women with type 1 or type 2 diabetes. Maternal glycaemia and BMI are the key modifiable risk factors. No maternity clinics were had appreciably better outcomes than any others, suggesting that health-care system changes are needed across all clinics (The Lancet Diabetes & Endocrinology)

Categories: Gestational, News
Tags: Type 1 Diabetes, Type 2 Diabetes

Categories: Gestational
Tags: Type 1 Diabetes, Type 2 Diabetes

A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial

January 19th 2021

Hyperglycaemia was reduced without increasing hypoglycaemia in adolescents and young adults with type 1 diabetes using the investigational advanced hybrid closed-loop system compared with the commercially available MiniMed 670G system (The Lancet)

Categories: News, Treatment
Tags: insulin pumps, pumps, Type 1 Diabetes

Categories: Treatment
Tags: insulin pumps, pumps, Type 1 Diabetes

Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland

January 4th 2021

Overall risks of fatal or critical care unit-treated COVID-19 were substantially elevated in those with type 1 and type 2 diabetes compared with the background population. The risk of fatal or critical care unit-treated COVID-19, and therefore the need for special protective measures, varies widely among those with diabetes but can be predicted reasonably well using previous clinical history (The Lancet Diabetes & Endocrinology)

Categories: News, Pathology
Tags: COVID-19, Type 1 Diabetes, Type 2 Diabetes

Categories: Pathology
Tags: COVID-19, Type 1 Diabetes, Type 2 Diabetes

Comparing the bone mineral density among male patients with latent autoimmune diabetes and classical type 1 and type 2 diabetes, and exploring risk factors for osteoporosis

January 3rd 2021

Compared with male patients with T2DM, lower BMDs were observed in patients with LADA and T1DM. Low BMI, uric acid, C-peptide levels, and high osteocalcin levels are risk factors for developing low BMD in male patients with diabetes (Journal of Endocrinological Investigation)

Categories: News, Pathology
Tags: lada, Osteoporosis, Type 1 Diabetes, Type 2 Diabetes

Categories: Pathology
Tags: lada, Osteoporosis, Type 1 Diabetes, Type 2 Diabetes

Diabetes (type 1 and type 2) in children and young people: diagnosis and management

December 16th 2020

This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18 (NICE)

Categories: News, Paediatrics
Tags: Type 1 Diabetes, Type 2 Diabetes

Categories: Paediatrics
Tags: Type 1 Diabetes, Type 2 Diabetes

Adult-onset autoimmune diabetes: comparative analysis of classical and latent presentation

December 7th 2020

Patients with classic T1DM presented more often with symptoms, lower BMI and higher number of autoantibodies, which may be related to a more aggressive autoimmune process. Patients with LADA developed more frequently microvascular complications for the same disease duration, namely diabetic nephropathy, and had more often metabolic syndrome (Diabetology & Metabolic Syndrome)

Categories: News, Pathology
Tags: lada, Type 1 Diabetes

Categories: Pathology
Tags: lada, Type 1 Diabetes

Type 1 and type 2 diabetes after gestational diabetes: a 23 year cohort study

November 20th 2020

All women with GDM should be intensively monitored for a decade, after which the risk for type 1 diabetes is minimal. However, the incidence of type 2 diabetes remains linear, and therefore individualised lifelong follow-up is recommended (Diabetologia)

Categories: Gestational, Monitoring, News
Tags: Type 1 Diabetes, Type 2 Diabetes

Categories: Gestational, Monitoring
Tags: Type 1 Diabetes, Type 2 Diabetes

Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes

November 19th 2020

Among children and young adults with newly diagnosed overt type 1 diabetes, golimumab resulted in better endogenous insulin production and less exogenous insulin use than placebo (NEJM)

Categories: Medication, News
Tags: golimumab, Type 1 Diabetes

Categories: Medication
Tags: golimumab, Type 1 Diabetes

Visit‐to‐visit variability of clinical risk markers in relation to long‐term complications in type 1 diabetes

November 12th 2020

In type 1 diabetes, higher variability of basic clinical risk markers adds important risk stratification information for the development of micro‐ and macrovascular complications (Diabetic Medicine)

Categories: Monitoring, News
Tags: glycaemic control, Type 1 Diabetes

Categories: Monitoring
Tags: glycaemic control, Type 1 Diabetes

Risk of cardiac autonomic neuropathy in latent autoimmune diabetes in adults is similar to type 1 diabetes and lower compared to type 2 diabetes: a cross sectional study

November 11th 2020

This is the first study offering a comparative evaluation of cardiac autonomic neuropathy among LADA, type 1 and type 2 diabetes, showing a lower risk of cardiac autonomic neuropathy in LADA compared to type 2 diabetes and similar compared to type 1 diabetes. This disparity was not due to differences in age, metabolic control or cardiovascular risk factors (Diabetic Medicine)

Categories: Cardiovascular, News
Tags: lada, Type 1 Diabetes, Type 2 Diabetes

Categories: Cardiovascular
Tags: lada, Type 1 Diabetes, Type 2 Diabetes

Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial

October 29th 2020

FMT halts decline in endogenous insulin production in recently diagnosed patients with T1D in 12 months after disease onset. Several microbiota-derived plasma metabolites and bacterial strains were linked to preserved residual beta cell function. This study provides insight into the role of the intestinal gut microbiome in T1D(BMC Gut)

Categories: News, Treatment
Tags: microbiome, Type 1 Diabetes

Categories: Treatment
Tags: microbiome, Type 1 Diabetes

The Prevalence of Autoimmune Diseases in Longstanding Diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes

October 27th 2020

Lifetime risk of autoimmune disease in longstanding T1D approaches 50%, is greater in females, and is driven by thyroid disease. The probability of diabetes complications such as CVD was lower in those with autoimmune disease, which was driven mostly by non-thyroid autoimmune diseases (Canadian Journal of Diabetes)

Categories: News, Pathology
Tags: autoimmune, Type 1 Diabetes

Categories: Pathology
Tags: autoimmune, Type 1 Diabetes

Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes

October 23rd 2020

Several immunotherapies have demonstrated endogenous insulin preservation in recent-onset type 1 diabetes (T1D). We considered the primary results of rituximab, abatacept, teplizumab, alefacept, high-dose antithymocyte globulin (ATG), low-dose ATG, and low-dose ATG ± granulocyte-colony–stimulating factor trials in an attempt to rank the effectiveness of the agents studied. C-peptide 2-h area under the curve means were modeled using analysis of covariance (Diabetes Technology and Therapeutics)

Categories: News, Pathology
Tags: beta cell, Type 1 Diabetes

Categories: Pathology
Tags: beta cell, Type 1 Diabetes

Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes

October 13th 2020

Position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (Diabetologia)

Categories: Management, News
Tags: CGM, Type 1 Diabetes

Categories: Management
Tags: CGM, Type 1 Diabetes
  • 1
  • 2
  • 3
  • …
  • 18
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Novo NordiskSanofi DiabetesNapp DiabetesAstraZeneca

Silver Sponsors

About Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes CareAmgen

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 Empagliflozin exenatide GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes USA Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership